Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy

Immunotherapy using monoclonal antibodies targeting the PD-1/PD-L1 interaction has shown enormous success for various cancers. Despite their encouraging results in clinics, antibody-based checkpoint inhibitors have several limitations, such as poor tumor penetration. To address these limitations of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hao, Liu, Yanli, Zhao, Zhen, Li, Yuanke, Mustafa, Bahaa, Chen, Zhijin, Barve, Ashutosh, Jain, Akshay, Yao, Xiaolan, Li, Guangfu, Cheng, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013927/
https://www.ncbi.nlm.nih.gov/pubmed/35444660
http://dx.doi.org/10.3389/fimmu.2022.838966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013927/
https://www.ncbi.nlm.nih.gov/pubmed/35444660
http://dx.doi.org/10.3389/fimmu.2022.838966

Ejemplares similares